Mechanism of Action of Vedolizumab (Entyvio)
Introduction Vedolizumab is a humanized IgG1 monoclonal antibody used for the treatment of moderate to severe ulcerative colitis and Crohn’s disease. It selectively targets the gastrointestinal immune system, offering gut-specific immunomodulation with minimal systemic immunosuppression. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Intravenous infusion Bioavailability Not applicable (IV administration) Half-life ~25.5 days Volume … Read more